FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036691295> ?p ?o ?g. }

• W3036691295 endingPage "1560" @default.
• W3036691295 startingPage "1559" @default.
• W3036691295 abstract "With coronavirus disease 2019 (COVID-19), it is now clear that the preparedness of the healthcare system for the levels of morbidity and mortality that could occur with a serious pandemic, whether due to influenza or COVID-19, is uncertain, but what is certain is the need for vaccine platforms that can be rapidly developed and scaled up to combat current and future pandemics. Prior to the emergence of severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2), the virus that causes COVID-19, researchers were preparing for the next influenza pandemic. Influenza pandemics have occurred throughout history and continue to be a threat, but existing vaccines will be inadequate. Antibody responses induced by current influenza vaccines can protect against homologous viruses but are less effective against antigenic variants and provide little, if any, protection against genetically shifted viruses. In addition, the logistics and time frame for the manufacture and administration of conventional killed or live attenuated influenza virus vaccines require at least 6 months from the identification of a strain to vaccine distribution and then an additional 1–2 months for widespread delivery. Such a time frame will limit vaccine availability during a worldwide pandemic. A significant challenge, therefore, is to develop new vaccine strategies that have shortened production times. In addition, for influenza, and possibly SARS-CoV-2, the most effective pandemic vaccine will need to address genetic drift and shift by providing broad spectrum protection against divergent influenza strains. Such a universal influenza vaccine is believed to be possible if it can induce immune responses against conserved regions of influenza. Nucleic acid vaccines, including RNA and DNA vaccines, offer the greatest potential to meet these needs because they can be quickly designed to encode any viral sequence and manufactured rapidly, requiring minimal to no process development for new antigenic variants. As mRNA vaccines do not require costly and time-consuming cell-based manufacturing, culture, or fermentation, they can be rapidly produced through simple synthesis methods. In addition, the formulated products demonstrate improved stability and, in multiple phase I human clinical trials, have been shown to be very safe. Importantly, both DNA and RNA vaccines can be designed to precisely focus the response on any given antigen of the virus, including more conserved antigen sequences that will need to be targeted by a universal influenza vaccine capable of inducing immunity against both seasonal drift and unknown future pandemics. With the likelihood that the continued spread of SARS-CoV-2 could be exacerbated during flu season,1Singer B.D. COVID-19 and the next influenza season.Sci. Adv. 2020; (Published online May 29, 2020)https://doi.org/10.1126/sciadv.abd0086Crossref Scopus (28) Google Scholar the development of a universal influenza vaccine remains a high priority. Even before mRNA vaccines caught the world’s attention as the first COVID-19 vaccine approach to enter phase I human clinical trials,2Thanh Le T. Andreadakis Z. Kumar A. Gómez Román R. Tollefsen S. Saville M. Mayhew S. The COVID-19 vaccine development landscape.Nat. Rev. Drug Discov. 2020; 19: 305-306Crossref PubMed Scopus (1218) Google Scholar they were making quick headway as an emerging front-runner for a universal influenza vaccine. The first mRNA vaccines were investigated in the early 1990s, but they were not initially pursued due to poor stability, limited capacity for scale up, and inefficient in vivo delivery. Since then, improvements in the delivery and stability of mRNA vaccines have placed them at the forefront of the pandemic response for COVID-19 and, even before that, in preparation for the next influenza pandemic. These include incorporation of RNA structural and sequence elements as well as purification methods to increase antigen expression and RNA stability and the development of lipid nanoparticles to enhance intracellular delivery of RNA into cells.3Cullis P.R. Hope M.J. Lipid Nanoparticle Systems for Enabling Gene Therapies.Mol. Ther. 2017; 25: 1467-1475Abstract Full Text Full Text PDF PubMed Scopus (507) Google Scholar, 4Ball R.L. Bajaj P. Whitehead K.A. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization.Int. J. Nanomedicine. 2016; 12: 305-315Crossref PubMed Scopus (134) Google Scholar, 5Kaczmarek J.C. Kowalski P.S. Anderson D.G. Advances in the delivery of RNA therapeutics: from concept to clinical reality.Genome Med. 2017; 9: 60Crossref PubMed Scopus (429) Google Scholar, 6Sabnis S. Kumarasinghe E.S. Salerno T. Mihai C. Ketova T. Senn J.J. Lynn A. Bulychev A. McFadyen I. Chan J. et al.A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates.Mol. Ther. 2018; 26: 1509-1519Abstract Full Text Full Text PDF PubMed Scopus (345) Google Scholar, 7Zhao Y. Huang L. Lipid Nanoparticles for Gene Delivery.Adv. Genet. 2014; 88: 13-36Crossref PubMed Scopus (117) Google Scholar, 8Li B. Luo X. Dong Y. Effects of Chemically Modified Messenger RNA on Protein Expression.Bioconjug. Chem. 2016; 27: 849-853Crossref PubMed Scopus (88) Google Scholar, 9Karikó K. Muramatsu H. Welsh F.A. Ludwig J. Kato H. Akira S. Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.Mol. Ther. 2008; 16: 1833-1840Abstract Full Text Full Text PDF PubMed Scopus (868) Google Scholar, 10Karikó K. Muramatsu H. Ludwig J. Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.Nucleic Acids Res. 2011; 39: e142Crossref PubMed Scopus (488) Google Scholar, 11Thess A. Grund S. Mui B.L. Hope M.J. Baumhof P. Fotin-Mleczek M. Schlake T. Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.Mol. Ther. 2015; 23: 1456-1464Abstract Full Text Full Text PDF PubMed Scopus (323) Google Scholar, 12Kauffman K.J. Mir F.F. Jhunjhunwala S. Kaczmarek J.C. Hurtado J.E. Yang J.H. Webber M.J. Kowalski P.S. Heartlein M.W. DeRosa F. Anderson D.G. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo.Biomaterials. 2016; 109: 78-87Crossref PubMed Scopus (121) Google Scholar In this issue of Molecular Therapy, Freyn et al.13Freyn A.W. Ramos da Silva J. Rosado V.C. Bliss C.M. Pine M. Mui B.L. Tam Y.K. Madden T.D. de Souza Ferreira L.C. Weissman D. et al.A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.Mol Ther. 2020; 28 (this issue): 1569-1584Abstract Full Text Full Text PDF Scopus (131) Google Scholar describe the development of an intradermally delivered combination lipid nanoparticle (LNP) mRNA vaccine candidate and break down antibody and T cell responses to each antigen component as well as the efficacy associated with those responses. In terms of antigen selection, the authors decided on 3 structural gene-derived antigen candidates, including a previously described mini hemagglutinin (HA), comprising a structurally-optimized HA stem design, as well as neuraminidase (NA) and the matrix-2 (M2) ion channel and then a nonstructural gene-derived antigen based on the nucleoprotein (NP). Using a nucleoside-modified co-transcriptional RNA production and capping process followed by purification using a dsRNA-removal process, they then demonstrated low, single-dose potency in mice following LNP-formulated intradermal vaccination. While the potency of this approach has been previously attributed to this particular preparation and delivery method, the authors have provided additional insight into the effect of combining multiple mRNA-encoded antigens into a single immunization on immunogenicity and efficacy compared to the individual components administered independently. While the combination of all 4 vaccines was able to completely protect against escalating challenge doses of H1N1 as well as diverse heterologous challenge viruses, including drifted H1N1 variants, H5N8, and a chimeric H6 virus, neuraminidase (NA) alone was only protective against H1N1 challenges, including the high-dose challenge (500 × 50% lethal dose [LD50]). Additionally, while NP alone provided broad protection from mortality, albeit with varied levels of morbidity, this protection was not provided solely by antibody or T cells independently. In contrast, while broad protection with variable morbidity was observed following vaccination with either M2 or miniHA alone, with little to no protection at the high-dose challenge, this protection was largely mediated by antibodies alone. In all challenge cases, however, the combination of miniHA, M2, NA, and NP provided for complete protection from morbidity and mortality, even following a 500 × LD50 challenge. The observation that a combination vaccine does not appear to induce any interference and that resulting immune responses are consistent with an additive effect in mice supports the continued development of this approach in larger animal models and eventually humans. However, the complexities and costs associated with releasing 4 separate drug products for a single clinical trial, in this case, may necessitate the testing of a single mRNA candidate encoding these 4 antigen genes or evaluating fewer combinations to determine the minimal composition of a universal flu vaccine. Additionally, minimizing the number of antigens in the combination while adding a booster dose may alleviate the need for multiple vaccine candidates in a single product, as the authors showed that booster doses improved antibody responses as well as efficacy, particularly for the miniHA candidate where antibody affinity maturation may contribute to the improved morbidity outcome. With the emergence of COVID-19, the substantial progress made in the last 10 years in the development of new and better DNA and RNA vaccine technologies is suddenly coming of age as these technologies, long believed to have considerable potential for pandemic preparedness, are put to the test in the very real pandemic unfolding before us. The work reported here by Freyn et al.13Freyn A.W. Ramos da Silva J. Rosado V.C. Bliss C.M. Pine M. Mui B.L. Tam Y.K. Madden T.D. de Souza Ferreira L.C. Weissman D. et al.A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.Mol Ther. 2020; 28 (this issue): 1569-1584Abstract Full Text Full Text PDF Scopus (131) Google Scholar highlights the feasibility and considerable promise of combination mRNA vaccines for developing a universal influenza vaccine as a strategy that could pre-empt a possible future flu pandemic. While the jury is still out on whether or not these types of vaccines will prove safe and efficacious in the human population, we are certainly very close to finding out, with first-in-human data anticipated this year. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceFreyn et al.Molecular TherapyApril 19, 2020In BriefConserved influenza virus antigens delivered by mRNA-based vaccines were shown to provide protection from a diverse panel of influenza A virus challenge strains in a murine model. These data support the further development of this approach as a universal influenza virus vaccine. Full-Text PDF Open Archive" @default.
• W3036691295 created "2020-06-25" @default.
• W3036691295 creator A5021777037 @default.
• W3036691295 creator A5072931108 @default.
• W3036691295 date "2020-07-01" @default.
• W3036691295 modified "2023-09-27" @default.
• W3036691295 title "Preparing for Pandemics: RNA Vaccines at the Forefront" @default.
• W3036691295 cites W1538766821 @default.
• W3036691295 cites W2058647478 @default.
• W3036691295 cites W2162970812 @default.
• W3036691295 cites W2285232484 @default.
• W3036691295 cites W2413302280 @default.
• W3036691295 cites W2521176812 @default.
• W3036691295 cites W2564551688 @default.
• W3036691295 cites W2600400434 @default.
• W3036691295 cites W2630192492 @default.
• W3036691295 cites W2791854174 @default.
• W3036691295 cites W3015371627 @default.
• W3036691295 cites W3016394521 @default.
• W3036691295 cites W3030472894 @default.
• W3036691295 doi "https://doi.org/10.1016/j.ymthe.2020.06.017" @default.
• W3036691295 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7309706" @default.
• W3036691295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32579882" @default.
• W3036691295 hasPublicationYear "2020" @default.
• W3036691295 type Work @default.
• W3036691295 sameAs 3036691295 @default.
• W3036691295 citedByCount "6" @default.
• W3036691295 countsByYear W30366912952020 @default.
• W3036691295 countsByYear W30366912952021 @default.
• W3036691295 countsByYear W30366912952023 @default.
• W3036691295 crossrefType "journal-article" @default.
• W3036691295 hasAuthorship W3036691295A5021777037 @default.
• W3036691295 hasAuthorship W3036691295A5072931108 @default.
• W3036691295 hasBestOaLocation W30366912951 @default.
• W3036691295 hasConcept C104317684 @default.
• W3036691295 hasConcept C142724271 @default.
• W3036691295 hasConcept C159047783 @default.
• W3036691295 hasConcept C17744445 @default.
• W3036691295 hasConcept C2779134260 @default.
• W3036691295 hasConcept C3008058167 @default.
• W3036691295 hasConcept C524204448 @default.
• W3036691295 hasConcept C54355233 @default.
• W3036691295 hasConcept C67705224 @default.
• W3036691295 hasConcept C71924100 @default.
• W3036691295 hasConcept C86803240 @default.
• W3036691295 hasConcept C89623803 @default.
• W3036691295 hasConceptScore W3036691295C104317684 @default.
• W3036691295 hasConceptScore W3036691295C142724271 @default.
• W3036691295 hasConceptScore W3036691295C159047783 @default.
• W3036691295 hasConceptScore W3036691295C17744445 @default.
• W3036691295 hasConceptScore W3036691295C2779134260 @default.
• W3036691295 hasConceptScore W3036691295C3008058167 @default.
• W3036691295 hasConceptScore W3036691295C524204448 @default.
• W3036691295 hasConceptScore W3036691295C54355233 @default.
• W3036691295 hasConceptScore W3036691295C67705224 @default.
• W3036691295 hasConceptScore W3036691295C71924100 @default.
• W3036691295 hasConceptScore W3036691295C86803240 @default.
• W3036691295 hasConceptScore W3036691295C89623803 @default.
• W3036691295 hasIssue "7" @default.
• W3036691295 hasLocation W30366912951 @default.
• W3036691295 hasLocation W30366912952 @default.
• W3036691295 hasLocation W30366912953 @default.
• W3036691295 hasOpenAccess W3036691295 @default.
• W3036691295 hasPrimaryLocation W30366912951 @default.
• W3036691295 hasRelatedWork W3032320397 @default.
• W3036691295 hasRelatedWork W3103289217 @default.
• W3036691295 hasRelatedWork W3106370311 @default.
• W3036691295 hasRelatedWork W3108360120 @default.
• W3036691295 hasRelatedWork W3119540162 @default.
• W3036691295 hasRelatedWork W3152916563 @default.
• W3036691295 hasRelatedWork W4313474620 @default.
• W3036691295 hasRelatedWork W4327956415 @default.
• W3036691295 hasRelatedWork W4381432928 @default.
• W3036691295 hasRelatedWork W4381942459 @default.
• W3036691295 hasVolume "28" @default.
• W3036691295 isParatext "false" @default.
• W3036691295 isRetracted "false" @default.
• W3036691295 magId "3036691295" @default.
• W3036691295 workType "article" @default.